2004
DOI: 10.1634/theoncologist.9-3-282
|View full text |Cite
|
Sign up to set email alerts
|

New Chemotherapeutic Advances in Pancreatic, Colorectal, and Gastric Cancers

Abstract: Pancreatic, gastric, and colorectal cancers are major causes of morbidity and mortality worldwide. When curative surgical resection is not an option, these malignancies tend to respond very poorly to chemotherapy and carry a dismal prognosis. There is, therefore, an urgent need for novel treatment strategies for these cancers. Great strides have been made in colon cancer treatment with the recent introduction of several novel agents, including capecitabine, irinotecan, and oxaliplatin either alone or in combin… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

2
40
0

Year Published

2005
2005
2017
2017

Publication Types

Select...
8

Relationship

0
8

Authors

Journals

citations
Cited by 77 publications
(42 citation statements)
references
References 87 publications
2
40
0
Order By: Relevance
“…Although chemotherapy regimens offer at best a slight, albeit statistically significant, improvement in survival for patients with gastric cancer, they are associated with a degree of toxicity that limits their value as a palliative treatment (Vanhoefer et al, 2000;Schoffski, 2002;Diaz-Rubio, 2004).…”
Section: Discussionmentioning
confidence: 99%
“…Although chemotherapy regimens offer at best a slight, albeit statistically significant, improvement in survival for patients with gastric cancer, they are associated with a degree of toxicity that limits their value as a palliative treatment (Vanhoefer et al, 2000;Schoffski, 2002;Diaz-Rubio, 2004).…”
Section: Discussionmentioning
confidence: 99%
“…A variety of FOLFIRI regimens have been examined in the clinical setting (9-11); however, in this study we used the modified FOLFIRI regimen (biweekly irinotecan 150 mg/m 2 with LV 100 mg/m 2 and 5-FU 2,000 mg/m 2 ) for patients with AGC. We adopted an infusional 5-FU regimen due to low hematological toxicity levels observed compared to bolus 5-FU (12).…”
Section: Discussionmentioning
confidence: 99%
“…Docetaxel, a semi-synthetic member of the taxane family, has potential activity against human solid tumors including prostate cancers (Diaz-Rubio, 2004). However, the use of high-dose docetaxel induced significant toxicity (Tedesco et al, 2004;Sun et al, 2007), but low or moderate doses of docetaxel have no significant anti-cancer activity in patients (Ryan et al, 2002).…”
Section: Discussionmentioning
confidence: 99%
“…Docetaxel, a semisynthetic taxoid produced from the needles of the European yew (Taxus baccata) tree, is one of the most important active chemotherapeutic agents for human prostate cancers (Diaz-Rubio, 2004). However, the use of high-dose docetaxel induce significant toxicities such as asthenia, neuropathy, vertigo and tinnitus (Sarafraz and Ahmadi, 2008;Baker et al, 2009), whereas lowdose of docetaxel have no significant antitumor activity in patients (Ryan et al, 2002).…”
Section: Fig 1 Structure Of Thiacremonone (A) and Docetaxel (B)mentioning
confidence: 99%